<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GLATIRAMER ACETATE</span><br/>(gla-tir'a-mer)<br/><span class="topboxtradename">Copaxone, </span><span class="topboxtradename">Copolymer-1<br/></span><b>Classifications:</b> <span class="classification"> immunomodulator</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Glatiramer (formerly Copolymer-1) is a random synthetic copolymer of <small>L</small>-alanine, <small>L</small>-glutamic acid, <small>L</small>-lysine, and <small>L</small>-tyrosine. Its mechanism of action is unknown.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Its function is to reduce the relapse rate of multiple sclerosis (MS), a demyelinating disease of the CNS of unknown origin.
         During an autoimmune response, glatiramer is thought to divert immune cells away from their myelin target as occurs in multiple
         sclerosis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Reduction of the frequency of relapses in patients with relapsingremitting multiple sclerosis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to glatiramer acetate or mannitol.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B), lactation, children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Multiple Sclerosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 20 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Use recommended SC injection sites: Arms, abdomen, hips, and thighs.</li>
<li>Reconstitute with supplied diluent, swirl gently, let stand at room temperature until completely dissolved, then use immediately.</li>
<li>Do not store reconstituted drug. Before reconstitution, store vials at 20° to 10° C (4° to
            14° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Asthenia, back pain,</span> chills, facial edema, fever, <span class="speceff-common">flu-like syndrome, infection, pain, arthralgia.</span>
<span class="typehead">CNS:</span> Migraine, agitation, <span class="speceff-common">anxiety, hypotonia</span>. <span class="typehead">CV:</span>
<span class="speceff-common">Chest pain, palpitations,</span> syncope, tachycardia, <span class="speceff-common">vasodilation</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea, nausea,</span> anorexia, gastroenteritis, vomiting. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Dyspnea, rhinitis,</span> bronchitis. <span class="typehead">Skin:</span>
<span class="speceff-common">Rash, pruritus, sweating.</span>
<span class="typehead">Other:</span>
<span class="speceff-common">Postinjection reaction (flushing, chest pain, palpitations, anxiety, dyspnea, constriction of throat, urticaria), injection
         site reactions (erythema, hemorrhage, pain, pruritus, urticaria, swelling),</span> ecchymoses, <span class="speceff-common">lymphadenopathy,</span> ear pain, dysmenorrhea, urinary urgency. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1>Not studied. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: Indicated by longer remission periods and reduced frequency of attacks.</li>
<li>Assess for systemic postinjection reactions (see <small>PATIENT &amp; FAMILY EDUCATION</small>). Assure patient that reaction is self-limiting. Assess for local reactions at injection sites including erythema, itching,
            induration, and soreness.
         </li>
<li>Monitor for S&amp;S of compromised immune response (e.g., increasing frequency of infections).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Systemic postinjection reaction with chest pain, palpitations, flushing, urticaria, anxiety, dyspnea, and laryngeal constriction
            may occur immediately after injection. These symptoms are transient (lasting from 30 sec30 min), require no treatment,
            and resolve spontaneously.
            						
         </li>
<li>Notify physician of a planned or suspected pregnancy.</li>
<li>Report any distressing adverse drug effects.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>